5 Oct 2026, 11:46
Securities Administration—
BLSBLS PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
28 Sept 2026, 14:49
Securities Administration—
15 Sept 2026, 08:20
Director Interests—
14 Sept 2026, 08:25
Company Administration—
10 Sept 2026, 16:36
Securities Administration—
4 Sept 2026, 17:10
OtherMS
4 Sept 2026, 17:07
Securities Administration—
31 Aug 2026, 15:03
Company Administration—
31 Aug 2026, 12:51
Financial ResultsMS
31 Aug 2026, 12:44
Financial ResultsMS
31 Aug 2026, 12:37
Financial ResultsMS
31 Aug 2026, 12:36
Financial ResultsMS
27 Aug 2026, 11:51
Presentations—
13 Aug 2026, 08:12
Securities Administration—
30 July 2026, 16:59
Company Administration—
30 July 2026, 08:57
PresentationsMS
29 July 2026, 14:46
Presentations—
27 July 2026, 08:52
Quarterly ReportsMS
22 July 2026, 08:34
Company Update—
21 July 2026, 08:45
Company Update—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 5 Oct 2026, 11:46 | Application for quotation of securities - BLS | Securities Administration | — | 06020 | |
| 28 Sept 2026, 14:49 | Application for quotation of securities - BLS | Securities Administration | — | 06020 | |
| 15 Sept 2026, 08:20 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 14 Sept 2026, 08:25 | Angus Walker Appointed Alternate Director to Edward Myer | Company Administration | — | 12001 | |
| 10 Sept 2026, 16:36 | Application for quotation of securities - BLS | Securities Administration | — | 06020 | |
| 4 Sept 2026, 17:10 | S&P DJI Announces September 2026 Quarterly Rebalance | Other | MS | — | |
| 4 Sept 2026, 17:07 | Application for quotation of securities - BLS | Securities Administration | — | 06020 | |
| 31 Aug 2026, 15:03 | Appendix 4G Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 31 Aug 2026, 12:51 | BLS FY2027 Guidance | Financial Results | MS | 03003, 03021 | |
| 31 Aug 2026, 12:44 | BLS Investor Presentation | Financial Results | MS | 03003, 03026 | |
| 31 Aug 2026, 12:37 | BLS FY2026 Results Announcement | Financial Results | MS | 03003, 14014 | |
| 31 Aug 2026, 12:36 | Annual Report to shareholders | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 27 Aug 2026, 11:51 | BLS FY2026 Results Webinar 2 September 2026 8am AEST | Presentations | — | 03027, 14014 | |
| 13 Aug 2026, 08:12 | Application for quotation of securities - BLS | Securities Administration | — | 06020 | |
| 30 July 2026, 16:59 | BLS to Present at Coffee Microcaps 31/7/2026 at 11.30 am | Company Administration | — | 12008 | |
| 30 July 2026, 08:57 | BLS Pharmaceuticals Investor Webinar Presentation | Presentations | MS | 03026 | |
| 29 July 2026, 14:46 | BLS Q4 FY2026 Results Investor Webinar | Presentations | — | 14014 | |
| 27 July 2026, 08:52 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 03027, 19004, 19009 | |
| 22 July 2026, 08:34 | Agreement with Trexapharm for Commercialisation of Trexavive | Company Update | — | 11001 | |
| 21 July 2026, 08:45 | BLS Strengthens Gobal Psychedelic Medicines Platform | Company Update | — | 11001 |
1–20 of 20
1 / 1